Preface

Hematopathology

Mina L. Xu, MD

Editor

While hematopathology has long required the melding of morphology, routine laboratory test results, and advanced molecular/genetic data, recent years have brought an explosion of new ideas and information to the field. It has become ever more challenging for those in practice to sort out the emerging data for clinically relevant and actionable knowledge.

In this issue of *Surgical Pathology Clinics*, the authors hope to examine some of the controversial topics in hematopathology and also to provide a useful reference in areas that are not often systematically addressed. With regard to the former, these experts in the field have provided guidance in navigating the murky boundaries between mediastinal gray zone lymphomas and its mimics as well as between MDS, MPN, and MDS/MPN overlap syndromes. In addition, an in-depth assessment of optimal AML MRD testing is included. With regard to the latter, there are pathologic conditions of the bone for hematopathologists, establishment of criteria in Castleman lymphadenopathy as well as

a comprehensive overview of prognostic and predictive biomarkers in diffuse large B-cell lymphomas, some of which could lead to optimal selection of targeted therapeutics. Finally, important recent changes to the classification of specific lymphoid and myeloid neoplasms are presented with numerous illustrations.

I am excited to share this collection of select updates in and around our evolving field of hematopathology.

Mina L. Xu, MD
 Director of Hematopathology
 Associate Professor
 Department of Pathology and Laboratory
 Medicine
 Yale School of Medicine
 310 Cedar Street
 New Haven, CT 06510, USA

E-mail address:
mina.xu@yale.edu